158 related articles for article (PubMed ID: 443860)
41. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
42. Identification and solubilization of iodinated cell surface human melanoma associated antigens.
Bystryn JC; Smalley JR
Int J Cancer; 1977 Aug; 20(2):165-72. PubMed ID: 70412
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
Zörnig I; Halama N; Lorenzo Bermejo J; Ziegelmeier C; Dickes E; Migdoll A; Kaiser I; Waterboer T; Pawlita M; Grabe N; Ugurel S; Schadendorf D; Falk C; Eichmüller SB; Jäger D
Int J Cancer; 2015 Jan; 136(1):138-51. PubMed ID: 24839182
[TBL] [Abstract][Full Text] [Related]
44. In vivo delayed hypersensitivity reactions to partially purified human melanoma antigens.
Sutherland CM; Leong SP; Cooperband SR; Deckers PJ; Hornung MO; Krementz ET
J Surg Oncol; 1982 Aug; 20(4):221-6. PubMed ID: 7109625
[TBL] [Abstract][Full Text] [Related]
45. Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemotherapy of malignant melanoma.
Hollinshead A; Arlen M; Yonemoto R; Cohen M; Tanner K; Kundin WD; Scherrer J
Cancer; 1982 Apr; 49(7):1387-404. PubMed ID: 7059953
[TBL] [Abstract][Full Text] [Related]
46. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
47. Shared antigens between human malignant melanoma cells and Mycobacterium bovis (BCG).
Minden P; Sharpton TR; McClatchy JK
J Immunol; 1976 May; 116(5):1407-14. PubMed ID: 58033
[TBL] [Abstract][Full Text] [Related]
48. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells.
Savage HE; Rossen RD; Hersh EM; Freedman RS; Bowen JM; Plager C
Cancer Res; 1986 Apr; 46(4 Pt 2):2127-33. PubMed ID: 3948184
[TBL] [Abstract][Full Text] [Related]
49. [Immunologic response in patients with melanoma of the skin].
Mutsenietse AIa; Volrat AA; Popena BA; Bumbieris IaV; Shapovalova EA
Vopr Onkol; 1983; 29(4):34-8. PubMed ID: 6858048
[TBL] [Abstract][Full Text] [Related]
50. Leukocyte adherence inhibition and specific immunoreactivity in malignant melanoma.
Halliday WJ; Maluish AE; Little JH; Davis NC
Int J Cancer; 1975 Oct; 16(4):645-58. PubMed ID: 51836
[TBL] [Abstract][Full Text] [Related]
51. [Evidence for tumor immunity in human malignant melanoma].
Nagel GA
Schweiz Med Wochenschr; 1970 Jun; 100(23):995-1000. PubMed ID: 4947017
[No Abstract] [Full Text] [Related]
52. A comparative study of natural cytotoxicity and the leukocyte migration inhibition in human melanoma stages I and II.
Kristensen E
J Cancer Res Clin Oncol; 1980; 96(2):181-91. PubMed ID: 7391115
[TBL] [Abstract][Full Text] [Related]
53. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
54. Monoclonal antibodies to human melanoma associated antigens: study of their specificity and visualization at the cellular level of the antigenic distribution.
Libert A; Ghanem G; Arnould R; Vercammen-Grandjean A; Carrel S; Lejeune F
Anticancer Res; 1983; 3(4):219-25. PubMed ID: 6576727
[TBL] [Abstract][Full Text] [Related]
55. Isolation of a soluble tumor-associated antigen from human melanoma.
Roth JA; Holmes EC; Reisfeld RA; Slocum HK; Morton DL
Cancer; 1976 Jan; 37(1):104-10. PubMed ID: 1247946
[TBL] [Abstract][Full Text] [Related]
56. Humoral immunity in malignant skin melanoma. Isolation of melanoma specific IgG from melanoma metastases.
Kristensen E; Langvad E; Reimann R
Eur J Cancer (1965); 1976 Dec; 12(12):945-50. PubMed ID: 1009994
[No Abstract] [Full Text] [Related]
57. Isolation and characterization of a heterodimeric surface antigen on human melanoma cells and evidence that it is the 4F2 cell activation/proliferation molecule.
Dixon WT; Sikora LK; Demetrick DJ; Jerry LM
Int J Cancer; 1990 Jan; 45(1):59-68. PubMed ID: 2404879
[TBL] [Abstract][Full Text] [Related]
58. Growth and spontaneous regression of swine melanoma: relationship of in vitro leukocyte reactivity.
Berkelhammer J; Ensign BM; Hook RR; Hecker CJ; Smith GD; Oxenhandler RW
J Natl Cancer Inst; 1982 Mar; 68(3):461-8. PubMed ID: 6950174
[TBL] [Abstract][Full Text] [Related]
59. Human thoracic duct cannulation: manipulation of tumor-specific blocking factors in a patient with malignant melanoma.
Isbister WH; Noonan FP; Halliday WJ; Clunie GJ
Cancer; 1975 May; 35(5):1465-71. PubMed ID: 1122496
[TBL] [Abstract][Full Text] [Related]
60. Breast cancer skin test antigens of increased sensitivity prepared from vesicular stomatitis virus-infected tumor cells.
Austin FC; Boone CW; Levin DL; Cavins JA; Djerassi I; Rosner D; Case R; Klein E
Cancer; 1982 May; 49(10):2034-42. PubMed ID: 6280832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
